With preventive healthcare, the lifetime expenditures of management could be reduced by reactive prevention or avoided altogether because of proactive prevention.
The mean lifetime costs of managing stage 0 (US $1316) are significantly lower than those of stages 1 4 of invasive cancer (US $7020, $10,133, $11,120 and $10,015, respectively), indicating the saving of lifetime expenditures for early detection and treatment [4].
Taking the differences between the 10-year and lifetime expenditures for the baseline and alternative scenarios, we obtained the average gross per capita savings for both temporary and permanent 10%and15%5% weight loss.
The largest number of new patients falls within the 10 to 19 age group, which consequently faces the greatest share of expected lifetime expenditures due to T1D.
The difference between the present value of expected lifetime expenditures of patients with T1D and that of their matched counterparts is attributable to T1D.
In contrast to other studies [ 12, 38], we find substantial differences in lifetime expenditures between health scenarios.
Remaining lifetime expenditures show some considerable differences between scenarios, especially between the compression of morbidity scenarios and the others.
The younger the age of diagnosis, the higher the EYLL (Table 1), and, in general, the earlier the stage of diagnosis, the smaller the lifetime expenditures paid by the NHI.
